Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 7/2011

01-07-2011 | Original article

Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells

Authors: Masato Kato, Yutaro Nakamura, Takafumi Suda, Yuichi Ozawa, Naoki Inui, Naohiro Seo, Toshi Nagata, Yukio Koide, Pawel Kalinski, Hirotoshi Nakamura, Kingo Chida

Published in: Cancer Immunology, Immunotherapy | Issue 7/2011

Login to get access

Abstract

Staphylococcal enterotoxins A (SEA) and B (SEB) are classical models of superantigens (SAg), which induce potent T-cell-stimulating activity by forming complexes with MHC class II molecules on antigen-presenting cells. This large-scale activation of T-cells is accompanied by increased production of cytokines such as interferon-γ (IFN-γ). Additionally, as we previously reported, IFN-γ-producing CD8+ T cells act as “helper cells,” supporting the ability of dendritic cells to produce interleukin-12 (IL-12)p70. Here, we show that DC pulsed with SAg promote the enhancement of anti-tumor immunity. Murine bone marrow-derived dendritic cells (DC) were pulsed with OVA257–264 (SIINFEKL), which is an H-2Kb target epitope of EG7 [ovalbumin (OVA)-expressing EL4] cell lines, in the presence of SEA and SEB and were subcutaneously injected into naïve C57BL/6 mice. SAg plus OVA257–264-pulsed DC vaccine strongly enhanced peptide-specific CD8+ T cells exhibiting OVA257–264-specific cytotoxic activity and IFN-γ production, leading to the induction of protective immunity against EG7 tumors. Furthermore, cyclophosphamide (CY) added to SAg plus tumor-antigens (OVA257–264, tumor lysate, or TRP-2) pulsed DC immunization markedly enhanced tumor-specific T-cell expansion and had a significant therapeutic effect against various tumors (EG7, 2LL, and B16). Superantigens are potential candidates for enhancing tumor immunity in DC vaccines.
Literature
1.
White J, Herman A, Pullen AM et al (1989) The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal depetion in neonatal mice. Cell 56:27–35PubMedCrossRef
2.
Li H, Liera A, Tsuchiya D et al (1998) Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B. Immunity 9:807–816PubMedCrossRef
3.
Malchiodi EL, Eisenstein E, Fields BA et al (1995) Superantigen binding to a T cell receptor betachain of known three-dimensional structure. J Exp Med 182:1833–1845PubMedCrossRef
4.
Sundberg EJ, Li H, Liera AS et al (2002) Structures of two streptococcal superantigens bound to TCR beta chains reveal diversity in the architecture of T cell signaling complexs. Structure 10:687–699PubMedCrossRef
5.
Kotzin BL, Leung DYM, Kappler J, Marrack P (1993) Superantigen and their potential role in human disease. Adv Immunol 54:99–166PubMedCrossRef
6.
7.
Litton MJ, Sander B, Murphy E et al (1994) Early expression of cytokines in lymph nodes after treatment in vivo with Staphylococcus enterotoxin B. J Immunol Methods 175:47–58PubMedCrossRef
8.
Kawabe Y, Ochi A (1991) Programmed cell death and extrathymic reduction of V beta8+ CD4+ T cells in mice tolerant to Staphylococcal aureus enterotoxin B. Nature 349:245–248PubMedCrossRef
9.
Heeg K, Gaus H, Griese D, Bendig S, Miethke T, Wagner H (1995) Superantigen-reactive T cells that display an anergic phenotype in vivo appear functional in vivo. Int Immunol 7:105–114PubMedCrossRef
10.
Sundstedt A, Dohlsten M, Hedlund G, Hoiden I, Bjorklund M, Kalland T (1994) Superantigens anergize cytokine production but not cytotoxity in vivo. Immunology 82:117–125PubMed
11.
Bhardwaj N, Fried man SM, Cole BC, Nisanian AJ (1992) Cendritic cells are potent antigen-presenting cells for microbial superantigens. J Exp Med 175:267–273PubMedCrossRef
12.
Bhrardwaj N, Young JW, Nisanian AJ, Baggers J, Steinman RM (1993) Small amounts of superantigens, when presented on dendritic cells, are sufficient to initiatiate to T cellresponses. J Exp Med 178:633–642CrossRef
13.
Gurunathan S, Stobie L, Prussin C et al (2001) Requirements for the maintenance of Th1 immunity in vivo following DNAvaccination: A potential immunoregulatory role for CD8+ T cells. J Immunol 16:1283–1289
14.
Wang B, Norbury CC, Greenwood R, Bonnink JR, Yewdell Jw, Frelinger JA (2001) Multiple paths for activation of naïve CD8+ T cells: CD4-independent help. J Immunol 167:1283–1289PubMed
15.
Mailliard RB, Egawa S, Cai Q et al (2002) Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med 195:473–483PubMedCrossRef
16.
Nakamura Y, Watchmaker P, Urban J et al (2007) Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res 67:10012–10018PubMedCrossRef
17.
Osada T, Clay TM, Woo CY, Morse MA, Lyerly HK (2006) Dendritic cell-based immunotherapy. Int Rev Immunol 25:377–413PubMedCrossRef
18.
Fazle Akbar SMF, Abe M, Yoshida O, Murakami H, Onji M (2006) Dendritic cell-based therapy as a multidisciplinary approach to cancer treatment: present limitations and future scopes. Curr Med Chem 13:3113–3119PubMedCrossRef
19.
Lutsiak MEC, Semnani RT, Pascalis RD, Kashmiri SVS, Schlom J, Sabzevari H (2005) Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862–2868PubMedCrossRef
20.
Ito T, Seo N, Yagi H, Tsujimura K, Takigawa M, Tokura Y (2003) Alterations of immune functions in barrier disrupted skin by UVB irradiation. J Dermatol Sci 33:151–159PubMedCrossRef
21.
Nakamura Y, Suda T, Nagata T et al (2003) Induction of protective immunity to Listeria monocytogenes with dendritic cells retrovirally transduced with a cytotoxic T lymphocyte epitope minigene. Infect Immun 71:1748–1754PubMedCrossRef
22.
Enomoto N, Nagata T, Suda T et al (2007) Immunization with dendritic cells loaded with alpha-galactosylceramide at priming phase, but not at boosting phase, enhances cytotoxic T lymphocyte activity against infection by intracellular bacteria. FEMS Immunol Med Microbiol 51:350–362PubMedCrossRef
23.
Ozawa Y, Suda T, Nagata T et al (2009) Mucosal vaccine using CTL epitope-pulsed dendritic cells confers protection for intracellular pathogen. Am J Respir Cell Mol Biol 41:440–448PubMedCrossRef
24.
Kominsky SL, Torres BA, Hobeika AC, Lake FA, Johnson HM (2001) Superantigen enhanced protection against a weak tumor-specific melanoma antigen: implications for prophylactic vaccination against cancer. Int J Cancer 94:834–841PubMedCrossRef
25.
Muraille E, Trez DC, Pajak B, Brait M, Urbain J, Leo O (2002) T cell-dependent maturation of dendritic cells in response to bacterial superantigens. J Immunol 168:4352–4360PubMed
26.
Egwu CE, Li W, Yu C-R et al (2006) Interferone-γ induce regression of epithelial cell carcinoma: critical role of IRF-1 and ICSBP transcription factors. Oncogene 25:3670–3679CrossRef
27.
Kortylewski M, Komyod W, Kauffmann M-E et al (2004) Interferone-γ-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J Invest Dermatol 122:414–422PubMedCrossRef
28.
He XZ, Wang L, Zhang YY (2008) An effective vaccine against colon cancer in mice: use of recombinant adenovirus interleukin-12 transduced dendritic cells. World J Gastroenterol 14:532–540PubMedCrossRef
29.
Iinuma H, Okinaga K, Fukushima R et al (2006) Superior protective and therapeutic effect of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma. J Immunol 176:3461–3469PubMed
30.
Kim CH, Hong MJ, Park SD et al (2006) Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12. Cancer Immunol Immunother 55:1309–1319PubMedCrossRef
31.
Matsushita N, Shari AP-T, Martin LM, Riker AI (2008) Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 333:167–179PubMedCrossRef
32.
Valzasina B, Piconese S, Guiducci C, Colombo MP (2006) Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res 66:4488–4495PubMedCrossRef
33.
Zhou G, Drake GC, Levitsky IH (2006) Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107:628–636PubMedCrossRef
34.
Liu JY, Wu Y, Zhang XS et al (2007) Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother 56:1597–1604PubMedCrossRef
35.
Wirth S, Bille F, Koenig S et al (2002) Testing mouse mammary virus superantigen as adjuvant in cytotoxic T-lymphcyte responses against a melanoma tumor antigen. Int J Cancer 99:201–206PubMedCrossRef
36.
Cheng JD, Babb JS, Langer C et al (2004) Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. J Clin Oncol 22:602–609PubMedCrossRef
37.
Fangming Xiu, Cai Z, Yang Y, Wang X, Wang J, Cao X (2007) Surface anchorage of superantigen SEA promotes induction of specific antitumor immune response by tumor-derived exosomes. J Mol Med 85:511–521CrossRef
38.
Ren S, Terman DS, Bohach G et al (2004) Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and and a survival benefit in non-small cell lung cancer. Chest 125:1529–1539CrossRef
Metadata
Title
Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells
Authors
Masato Kato
Yutaro Nakamura
Takafumi Suda
Yuichi Ozawa
Naoki Inui
Naohiro Seo
Toshi Nagata
Yukio Koide
Pawel Kalinski
Hirotoshi Nakamura
Kingo Chida
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 7/2011
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1015-5

Other articles of this Issue 7/2011

Cancer Immunology, Immunotherapy 7/2011 Go to the issue

Original article

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice

Original article

Identification of Hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas

Short communication

Gastric type I carcinoid: a pilot study with human G17DT immunogen vaccination

Original article

Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma

Review

Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer

Original article

Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits